These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 33489907

  • 21. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M, Mannaerts CK, Nieboer D, Beerlage HP, Wijkstra H, Mulders PFA, Roobol MJ.
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [Abstract] [Full Text] [Related]

  • 22. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo C, Gallucci M, Catalano C.
    Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO.
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [Abstract] [Full Text] [Related]

  • 25. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
    Trottier G, Roobol MJ, Lawrentschuk N, Boström PJ, Fernandes KA, Finelli A, Chadwick K, Evans A, van der Kwast TH, Toi A, Zlotta AR, Fleshner NE.
    BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
    [Abstract] [Full Text] [Related]

  • 26. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
    Dwivedi DK, Kumar R, Dwivedi AK, Bora GS, Thulkar S, Sharma S, Gupta SD, Jagannathan NR.
    J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
    [Abstract] [Full Text] [Related]

  • 27. An analysis of three different prostate cancer risk calculators applied prior to prostate biopsy: A Turkish cohort validation study.
    Yıldızhan M, Balcı M, Eroğlu U, Asil E, Coser S, Özercan AY, Köseoğlu B, Güzel O, Asfuroğlu A, Tuncel A.
    Andrologia; 2022 Mar; 54(2):e14329. PubMed ID: 34837424
    [Abstract] [Full Text] [Related]

  • 28. PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer.
    Steuber T, Heidegger I, Kafka M, Roeder MA, Chun F, Preisser F, Palisaar RJ, Hanske J, Budaeus L, Schiess R, Keller T, Semjonow A, Hammerer P, Manka L, Ecke T, Schwentner C, Ohlmann C.
    Eur Urol Oncol; 2022 Jun; 5(3):321-327. PubMed ID: 33422560
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A, Dell'Oglio P, De Cobelli F, Esposito A, Gandaglia G, Fossati N, Brembilla G, Cristel G, Cardone G, Deho' F, Losa A, Suardi N, Gaboardi F, Del Maschio A, Montorsi F, Briganti A.
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [Abstract] [Full Text] [Related]

  • 38. Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina.
    Orbe Villota PM, Leiva Centeno JA, Lugones J, Minuzzi PG, Varea SM.
    Actas Urol Esp (Engl Ed); 2024 Apr; 48(3):210-217. PubMed ID: 37827241
    [Abstract] [Full Text] [Related]

  • 39. Comparison of Two Prostate Cancer Risk Calculators that Include the Prostate Health Index.
    Roobol MJ, Vedder MM, Nieboer D, Houlgatte A, Vincendeau S, Lazzeri M, Guazzoni G, Stephan C, Semjonow A, Haese A, Graefen M, Steyerberg EW.
    Eur Urol Focus; 2015 Sep; 1(2):185-190. PubMed ID: 28723432
    [Abstract] [Full Text] [Related]

  • 40. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.
    Dell'Oglio P, Stabile A, Soligo M, Brembilla G, Esposito A, Gandaglia G, Fossati N, Bravi CA, Dehò F, De Cobelli F, Montorsi F, Karnes RJ, Briganti A.
    Eur Urol Oncol; 2020 Feb; 3(1):112-118. PubMed ID: 31411973
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.